Portugal

Population (January 2013):	10 487 289
Human development Index (2013):	0.822
HAV vaccine recommendations:	HAV vaccination is recommended for: 1. travellers to high or intermediate endemic countries 2. adolescents and adults with chronic liver disease 3. for outbreak control.
Seroprevalence studies by quality score:	score 0: 3 studies; score 1: 3 studies; score 2: 2 studies
Seroprevalence studies timeframe:	1983–2007

Seroprevalence assessment: **low**
Incidence assessment: **very low**
Susceptibility in adults: **low**

The only study published in Portugal before 1990 (Lecour 1984), estimated an HAV seroprevalence to be above 50% by 15 years with less than 90% seroprevalence by10 years (Figure 1).

Out of 5 studies estimating HAV seroprevalence in Portugal between 1990 and 1999, only three provided estimates of seroprevalence by 30 and 15 years old. The seroprevalence estimates are above 50% in all 3 studies by the age of 30; while only one study reports seroprevalence above 50% by the age of 15 (Figure 1).

Two studies conducted after 2000 estimated HAV seroprevalence to be around or over 50% by the age of 30 . Therefore, Portugal likely transitioned from intermediate to low endemicity in the 1990s (Figure 1), and remains a low endemicity country after 2000**.**

Portugal_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Reported incidence data in Portugal is available from TESSy (Figure 2) since 2006. It shows a very low incidence below 0.5 per 100 000.

The susceptibility among adults is low, as susceptibility levels by 30 years are around 20% and by 50 years old less than 10% are susceptible.

Portugal_Figure 1 (panel a). Summary of seroprevalence in Portugal, by age and time period.

Panel a.1: 1975–1989



Panel a.2: 1990–1999



Panel a.3: 2000–2013



Portugal_Figure 1 (panel b). Summary of seroprevalence in Portugal, by age and time period (1975–2013).



Portugal_Figure 2. Reported incidence of hepatitis A, Portugal, 1989–2013.



Bibliography

1. Antunes H, Neiva F, Estrada A. Learn more in preventing infants' hepatitis a: The prevalence of hepatitis a virus antibody in portuguese pregnant women population. J Pediatr Gastroenterol Nutr. 2009;48:E65-E6.

2. Barros H, Oliveira F, Miranda H. A survey on hepatitis A in Portuguese children and adolescents. J Viral Hepat. 1999 May;6(3):249-53.

3. Cunha I, Antunes H. [Prevalence of antibodies against hepatitis A virus in a population from northern Portugal]. Acta Med Port. 2001 Sep-Dec;14(5-6):479-82.

4. Lecour H, Ribeiro AT, Amaral I, Rodrigues MA. Prevalence of viral hepatitis markers in the population of Portugal. Bull World Health Organ. 1984;62(5):743-7.

5. Leitao S, Santos RM, Santos JC, Ferreira R, Goncalves FN, Coutinho P, et al. Hepatitis a prevalence in rural and urban Portuguese populations. Eur J Intern Med. 1996;7(2):119-21.

6. Macedo G, Ribeiro T. Hepatitis A: Insights into new trends in epidemiology [1]. Eur J Gastroenterol Hepatol. 1998;10(2):175.

7. Marinho RT, Valente AR, Ramalho FJ, de Moura MC. The changing epidemiological pattern of hepatitis A in Lisbon, Portugal. Eur J Gastroenterol Hepatol. 1997 Aug;9(8):795-7.

8. Pereira S, Linhares I, Neves AF, Almeida A. Hepatitis a immunity in the district of Aveiro (Portugal): An Eleven-year surveillance study (2002-2012). Viruses. 2014;6(3):1336-45.